UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2017
BIOANALYTICAL SYSTEMS, INC. |
(Exact name of registrant as specified in its charter) |
Indiana | 0-23357 | 35-1345024 | ||
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
2701 KENT AVENUE WEST LAFAYETTE, INDIANA |
47906-1382 | |
(Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (765) 463-4527
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On June 14, 2017, the Board of Directors of Bioanalytical Systems, Inc. (the “Company”) unanimously elected Gregory C. Davis, Ph.D. as an independent, Class III director. Dr. Davis’ term will expire at the 2018 annual meeting of shareholders. The Board of Directors has not determined the committees of the Board of Directors to which Dr. Davis will be named. The Company will disclose that information once determined.
As a director of the Company, Dr. Davis will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices described in the Company’s Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on January 30, 2017. This compensation generally consists of cash payments (annual cash retainers and board and committee meeting fees) and such stock option awards as may be granted from time to time.
A copy of the press release announcing the election of Dr. Davis is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) | Exhibits: |
99.1 | Press Release dated June 20, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Bioanalytical Systems, Inc. | |||
Date: June 20, 2017 | By: | /s/ Jill C. Blumhoff | |
Jill C. Blumhoff | |||
Chief Financial Officer, | |||
Vice President of Finance |
Exhibit Index
Exhibit No. | Description |
99.1 | Press Release dated June 20, 2017 |
Exhibit 99.1
FOR MORE INFORMATION: | Company Contact: |
Jill Blumhoff | |
Chief Financial Officer & | |
Vice President of Finance | |
Phone: 765.497.8381 | |
jblumhoff@BASinc.com | |
BASi Names Dr. Gregory C. Davis to Board of Directors
WEST LAFAYETTE, IN, June 20, 2017 -- Bioanalytical
Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced that the board of directors unanimously
elected Dr. Gregory C. Davis as a director effective June 14, 2017. This action brings the number of directors to four.
Larry Boulet, BASi’s Chairman of the Board, commented, "We are delighted that Dr. Davis has joined our board. His strong
background in the pharmaceutical industry and proven leadership qualities will prove particularly valuable as we continue to focus
on strategies that drive growth for BASi."
Dr. Davis is currently running his own consulting firm, which he founded in 2012, assisting companies with regulatory and control strategy and product development issues. In 2014, Greg joined Calibrium, LLC as Vice President of CMC, Regulatory, and Quality. Calibrium was developing novel biotheraputics for the treatment of diabetes. The company was sold to Novo Nordisk in late 2015. From 1992 to 2012, Dr. Davis held various leadership positions at Eli Lilly in Biotechnology Product Development, Global Regulatory Affairs, Global Brand Teams, and Quality. One of the highlights of his Lilly career was being COO of the Xigris Product Team. Xigris was the first biotechnology product ever approved for the treatment of severe sepsis. When Greg retired from Eli Lilly in December of 2012, he was Executive Director and Senior Principle Fellow in Global Regulatory Affairs.
Dr. Davis has held numerous leadership positions within the Pharmaceutical Research and Manufacturers Association (PhRMA), the United States Pharmacopeia (USP), and the Biotechnology Industry Organization (BIO). He also served for five years as the PhRMA liaison to the International Conference on Harmonization (ICH) for Q5/Q6 Biotechnology topics. He coauthored several of the ICH guidances on registration standards for biotechnology products which are still in use today. Dr. Davis received his bachelor’s degree from Southeast Missouri State University and his Ph.D. in Analytical Chemistry from Purdue University studying under Dr. Peter Kissinger, founder of BASi.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more information about BASi.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.
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end